Analysis Of Short-term Efficacy And Safety Of Apatinib In The Treatment Of Gynecological Malignant Tumors

Objective: To observe the short-term efficacy and safety of apatinib in the treatment of gynecological cancer patients.Methods: In this study,we collected clinical data from patients with female reproductive system tumors who received oral apatinib from January 2017 to December 2018 in the First Hospital of Jilin University.All the patients had drug resistance or recurrence after second-line or more treatment.Every 3 to 4 weeks for 1 cycle,and the therapeutic effect can be evaluated after 2 cycles of treatment.Finally,31 patients with gynecological tumors can evaluate the short-term efficacy.The objective response rate(ORR),disease control rate(DCR)and adverse events were assessed bases on RECIST 1.1 standard and NCI-CTCAE 4.0.A retrospective analysis of case data was performed on patients with partial response(PR).Results: 1.All patients completed 2 cycles of treatment,which could evaluate the short-term efficacy.Among the 31 patients,there were no CR cases,8 PR cases(25.81%),14 SD cases(45.16%)and 9 PD cases(29.03%).The ORR and DCR were 25.81%(8/31)and 70.97%(22/31),respectively.2.Nineteen of the 31 patients had ovarian cancer.There were no CR cases,6 PR cases(31.58%),8 SD cases(42.11%)and 5 PD cases(26.32%).The ORR and DCR were 31.58%(6/19)and 73.68%(14/19),respectively.3.Nine of the 31 patients had cervical cancer.There were no CR cases,1 PR cases(11.11%),5 SD cases(55.56%)and 3 PD cases(33.33%).The ORR and DCR were 11.11%(1/9)and 66.67%(6/9),respectively.4.The correlation between different clinical data and short-term efficacy was analyzed by ORR and DCR.The results showed that Apatinib with tumor type,clinical stage,number of previous chemotherapy lines,initial dose and whether or not combined with other treatments were no significant statistical differences.5.31 patients had varying degrees of toxic side effects,the most common treatment-related adverse event were hypertension(n=16,51.61%),hand-foot syndrome(n=11,35.48%),diarrhea(n=9,29.03%),proteinuria(n=7,22.58%)and oral mucosa damage(n=6,19.36%).Conclusion: 1.Apatinib showed a good anti-tumor effect in female reproductive system tumors and had a positive short-term efficacy.It can be used as a medication option for patients with gynecological reproductive system tumors who have failed in second-line or more treatment.2.Toxic side effects: Most of them can be improved after symptomatic treatment,and a small number of patients can be improved after intermittent or reduction treatment.Most of the adverse reactions can be acceptable and manageable.